Centre for Human Drug Research’s Post

🎉 A Breakthrough in Treating Deadly Skin Disease: World-First Cure Achieved! In an incredible leap forward for medical science, researchers have successfully cured patients suffering from Toxic Epidermal Necrolysis (TEN), a rare and often fatal skin condition, through an innovative use of existing drugs. Published in Nature, this landmark study could pave the way for an approved curative therapy, offering hope where there was previously very little. 🔬 Study Highlights: ◾ TEN, characterized by severe skin blistering and a high mortality rate, was halted using JAK inhibitors, drugs already used for inflammatory diseases. ◾ The study not only saved lives but also opened new doors in the treatment of other severe skin disorders and inflammatory conditions. 🌍 Global Impact: This pioneering work represents a monumental step in dermatology and emergency medicine, showcasing the power of collaborative research and the repurposing of drugs to fast-track life-saving treatments. 🔗 https://lnkd.in/grttG9-Q #MedicalResearch #Dermatology #HealthcareInnovation #SkinDisease #LifeSavingResearch

Our Head of Clinical Operations, Leonie Middelink, and Scientist, Stephanie van Dalen, are looking forward to attending the 9th Annual Symposium on Hidradenitis Suppurativa Advances, taking place in Austin, Texas, from 1-3 November. During the conference Stephanie will share a poster on Citryll’s latest research in Hidradenitis Suppurativa (HS), titled "Neutrophil Extracellular Traps in HS skin and serum as a target for CIT-013, a NET targeting therapy". Be sure to check out our poster and discover how Citryll is revolutionizing the world of immune-mediated inflammatory diseases! Learn more about SHSA: https://lnkd.in/gBZZwg4f #SHSA2024 #Dermatology #NETosis #Citryll #ClinicalResearch

Productive week in Germany and Basel Switzerland! Big movements in Digital Health Technology for Oncology , CRS detection for CAR-T and BiTE Therapies, lets connect on our CRS Consortium , the pathway to community clinics. Also the rumors are true!!! Biofourmis is moving the needle in collaborations with our clinically validated Nocturnal Scratch and Sleep Algorithm partnership for Atopic Dermatitis. Our agnostic (algorithm, device and therapeutic) platform has the ability to measure quantitatively, passively and in an unbiased manner nocturnal scratching (# of events and duration) and sleep quantity to provide endpoints with high accuracy, specificity and sensitivity in patients from 2- 75 years of age. We give you the ability to assess AD symptomatology, burden and response to treatments all in one place. #DCT, #DCTstrategies, #DecentralizedClinicalTrials #DHT #ClinicalTrials #Regulatory #Validation #CART, #BiTE #Immunotherapy,#oncology #AtopicDermatitis #Dermatology #Psoriais #Eczema

Webcast Alert! Chronic Spontaneous Urticaria: A Targeted Approach. Urticaria is a condition characterized by the development of wheals (hives), angioedema, or both; it may be considered chronic if the symptoms persist for more than 6 weeks. In some patients, chronic urticaria will be spontaneous, meaning that triggers (whether known or unknown) inconsistently cause symptoms. Though relatively rare, chronic spontaneous urticaria (CSU) can be a debilitating, difficult-to-treat condition, hugely impacting patients’ quality of life in all domains. In order to direct patients with CSU to effective management regimens, clinicians first need to be confident in their ability to diagnose CSU. In this webcast, Brian S. Kim, MD, describes the pathophysiology of CSU, before delving into case examples and clinical trial evidence that support strategies for CSU management. Click here to start the webcast: https://bit.ly/3zCsHNV #Webcast #NACE #Dermatology

I'm thrilled to share that Our latest research, a randomized control trial published in the prestigious American Journal Mycoses with an impact factor of 4.9, sheds light on an important treatment comparison. Under the guidance of Dr. Avinash Khadela and Dr. Nayan Patel, and with the invaluable contributions of colleagues Tithi Shah and Mansi Rohit we conducted this trial. The focus of our RCT was the comparison of topical luliconazole with topical bland emollient in oral itraconazole regimen for disseminated dermatophytosis. As a result, Both treatment regimens exhibited no significant difference in safety, tolerability profiles and clinical cure. moreover, both regimens displayed similar clinical relapse profiles, highlighting the efficacy of both approaches. it's important to note that the addition of topical LUZ in the regimen resulted in a notable increase in therapy cost, a factor to consider in treatment decision-making. Our research not only adds to the body of knowledge in the field but also provides clinicians with valuable insights into treatment efficacy, safety, and cost considerations. We're proud to contribute to advancements in patient care and look forward to further discussions and collaborations in this important area of research. #dermatology #research #publication #pharmd #journal #medicalresearch #mycoses #clinicaltrials

EI Cure Project is pleased to announce our support for a 1-year research project led by Dr Leonie Frommherz and Professor Cristina Has: “Influence of inflammation parameters and signalling cascades for potential therapeutic approaches in Epidermolytic Ichthyosis: a comprehensive analysis integrating proteomic and RNA-Sequence data”. These two wonderful dermatology scientists were key members of the team who recently published the largest population study of EI ever seen: https://lnkd.in/e47a6eBF This new research project aims to build on this work and stands to become the largest evaluation of biological data on EI. Whilst the EI Cure Project is committed to finding a gene-editing solution to cure EI, we also recognise that the EI Community needs better options to relieve symptoms NOW! The aim of this new project is to understand those symptoms better by exploring diagnostic bio markers, and to hopefully identify some new therapeutic targets for drug repurposing. We are excited that this project could lead us to new solutions within the immediate future. Thank you so much Leonie and Cristina, it’s so great to have you in our corner! 🥰 #eicureproject #hope4ei #drugrepurposing #proteomics #RNAsequencedata #epidermolyticichthyosis #ichthyosisawareness #ichthyosisresearch #RAREderm #dermatology

We recently we had the great pleasure of meeting with some of the world’s leading experts in the fields of #Dermatology and #AtopicDermatitis, to discuss clinical development plans for the lead candidate in our pipeline of disease-modifying #Therapies for chronic #Autoimmune and #InflammatoryDiseases. SYX-5219, which will advance into the clinic for the treatment of atopic dermatitis, targets a critical enzyme regulating cell #Metabolism called pyruvate kinase M2 (PKM2) – a novel therapeutic target with the potential to rebalance the #ImmuneSystem, normalize immune cell function and drive sustained disease remission.    As we finalise our development plans for this candidate, it’s vital that we collaborate with, and learn from, those who are expert in the field and those who are treating patients today. A huge thank you to everyone who shared their time, knowledge, insights and real-world experiences – invaluable to us in ensuring our #Science can continue to progress at pace for the benefit of patients.   Find out more about the latest progress within Sitryx’s proprietary pipeline: https://lnkd.in/eS8FGNRx

💡Psoriasis Treatment is Evolving! 💡 Spherix Global Insights highlights the excitement around pipeline agents like Johnson & Johnson’s oral IL-23 asset, JNJ-2113, which reflects high expectations for it to capture significant market share, potentially outpacing other oral candidates and shifting the timelines for initiating biologic treatments. Competing with JNJ-2113 in the pipeline are several promising TYK2 inhibitors, including ESK-001 from Alumis, zasocitinib (TAK-279) from Takeda, and BMS-986322 from Bristol Myers Squibb. With patient preference shifting towards oral options, these innovative treatments could reshape the market and improve care. Read more: https://lnkd.in/e4JfAKMy #Psoriasis #Dermatology #EmergingTherapies #MarketResearch

#Hotoff_the_press: Proud of the dynamic duo Mahdi Saghari and Wouter ten Voorde who #together dedicated their last 6 years to innovate #clinicalpharmacology, #immunology and #skinscience with novel pharmacological models (#KLH, #SubstanceP, #imiquimod and #LPS) in healthy volunteers. The effects were monitored by various (non)invasive techniques, and serve as pharmacodynamic endpoints in early-phase #clinicalstudies of immunomodulatory compounds. Their work resulted in two excellent #PhD_theses: 'Keyhole limpet hemocyanin challenge model for studying adaptive immune responses in early-phase clinical drug development' & 'Rubor, Calor, Tumor, Dolor. Objective assessments of inflammation’ The public #double #PhDdefence will take place on #December17th at 10.00 am (Mahdi) and 13.00 (Wouter) at Leiden University. Please ping me if you would like to receive their theses! #Teamscience #Dermatology Centre for Human Drug Research Erasmus MC Department of Dermatology Leiden University Medical Center

I'm excited to announce that I will be participating as a speaker in an upcoming online webinar titled "Different Modes of Action in Atopic Dermatitis" on July 31, 2024, from 20:00 to 21:00. I will be presenting "Unraveling the Pathomechanisms of Atopic Dermatitis: Insights and Innovations," where I'll delve into the latest research and advancements in understanding and treating this complex condition. Joining me is Professor Alon Hershko, who will discuss "The Atopic March – Different Diseases with a Common Mechanism." Together, we aim to provide a comprehensive overview of atopic dermatitis and related conditions. The event will conclude with a panel discussion, allowing for an interactive and engaging session with our audience. For more details and registration, please refer to the following link: https://lnkd.in/dqUJAY6t. Looking forward to a productive session and hoping to see many of you there! #Dermatology #AtopicDermatitis #Webinar #MedicalEducation #Research